Most of these studies have so far focused on the targeting of the ATR/CHK1 pathway, with the idea that latent RS in MYC-dependent tumor cells might constantly engage ATR/CHK1 to prevent rampant genomic instability. The gene discussed is CHEK1; the disease is neoplasm.